The effects of ezetimibe and/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients.
Abstract
We investigated the factors influencing triglycerides (TG) reduction during ezetimibe, alone or combined with orlistat, administration. Eighty-six obese hypercholesterolemic subjects were prescribed a low-fat diet and were randomized to ezetimibe (E group), orlistat (O group), or both (OE group) for 6 months. Plasma TG and apolipoprotein (apo) C-III reduction was significantly greater in the combination group compared with monotherapy. Multivariate analysis showed that in E group apoC-III reduction and baseline TG levels were independently positively correlated, whereas baseline apoC-II levels were negatively correlated, with TG lowering. In OE group apoC-III reduction was the only independent contributor to TG reduction.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Orlistat is a pharmacological method to reduce fat absorption, which may be helpful in patients with fasting hyperchylomicronemia.
“It is a pharmacological method to reduce fat absorption, which may be helpful in patients with fasting hyperchylomicronemia (187).”
From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [187]
The citation lists haven’t been fetched yet
References 48 · Cited by 23
- Authors
- Nakou, E. S., Filippatos, T. D., Agouridis, A. P., Kostara, C., Bairaktari, E. T., & Elisaf, M. S.
- Affiliations
- University of Ioannina (GR)
- Corresponding author
- Elisaf, M. S.
- Venue
- Lipids
- Publisher
- Wiley
- Published
- 2010-04-09
- Volume
- 45
- Issue
- 5
- Pages
- 445-450
- ISSN
- 0024-4201 (ISSN-L)
- 1558-9307
- OpenAlex
- W2093616220
- Cited by
- 23
- References
- 48
- Citations by year
- 2021: 3 · 2018: 1 · 2016: 5 · 2015: 1 · 2014: 2 · 2013: 4 · 2012: 3
- FWCI
- 3.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Lipids (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Keywords
- ezetimibe, orlistat, triglyceride-rich lipoproteins, hypertriglyceridemia, apolipoprotein C-III, apolipoprotein C-II, triglyceride lowering, obesity, hypercholesterolemia, low-fat diet, combination therapy, lipoprotein metabolism
- MeSH terms
- Ezetimibe, Orlistat, Anticholesteremic Agents, Azetidines, Drug Therapy, Combination, Female, Humans, Lactones, Male, Middle Aged, Obesity, Triglycerides, Diet, Fat-Restricted, Anti-Obesity Agents, Apolipoprotein C-II, Apolipoprotein C-III
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
